News Headlines Article

New melanoma drugs have deep Bay Area roots
San Francisco Business Times

Zelboraf, the melanoma treatment approved Wednesday by the FDA, is a great Bay Area story — developed by Berkeley’s Plexxikon Inc. , marketed by South San Francisco’s Genentech Inc. and accelerated by a diagnostic test developed by Pleasanton’s Roche Molecular Diagnostics. You can’t get much more Bay Area than that. But Zelboraf isn’t the only new melanoma drug with a Bay Area connection. Bristol-Myers Squibb ’s Yervoy, approved by the Food and Drug in March, largely owes its development to research done by Dr. James Allison and colleagues in the mid-1990s at the University of California , Berkeley.